Shin Nippon Biomedical Laboratories,ltd. Stock price
Is Shin Nippon Biomedical Laboratories,ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Shin Nippon Biomedical Laboratories,ltd. Stock Analysis
Analyst Opinions
6 Analysts have issued a Shin Nippon Biomedical Laboratories,ltd. forecast:
Analyst Opinions
6 Analysts have issued a Shin Nippon Biomedical Laboratories,ltd. forecast:
Don't miss a Thing! We will send you all news about Shin Nippon Biomedical Laboratories,ltd. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 1,436 full-time employees. The company went IPO on 2004-03-08. The company operates through four business segments. CRO segment includes non-clinical business using laboratory animals, cells, and bacteria to confirm the efficacy and safety of drugs under development by pharmaceutical companies, and clinical business, conducting trials to confirm efficacy and safety in humans. Translational Research segment develops nasal delivery platform technologies and conducts non-clinical and clinical testing necessary for the evaluation and approval of pharmaceuticals and others. Medipolis segment operates accommodation facilities and geothermal power generation businesses. United States Real Estate segment rents out multi-purpose industrial buildings constructed on sites owned by its subsidiary. The company also undertakes administrative work and provides support for the group's operations.
| Head office | Japan |
| CEO | Mr. Nagata |
| Employees | 1,522 |
| Website | snbl.com |


